Cinacalcet in the treatment of secondary hyperparathyroidism
Keywords:
morbilidad, mortalidad, cinacalcet, hiperparatiroidismo, paratiroidectomíaAbstract
Secondary hyperparathyroidism (HPT) is characterized by an abnormal elevation in the secretion of parathyroid hormone (PTH) resulting from hyperplasia of the parathyroid glands. This condition is primarily triggered by factors such as hypocalcemia, hyperphosphatemia and active vitamin D deficiency, which cause alterations in both bone and mineral metabolism and can lead to significant cardiovascular complications. In patients with chronic kidney disease (CKD), secondary HPT frequently occurs, which worsens the clinical picture of those affected. Cinacalcet, a calcium receptor modulator, has emerged as an innovative therapeutic option to control elevated PTH levels in these patients, thus reducing associated complications. The objective of this research consists to describe the use of cinacalcet in the treatment of secundary hyperparathyroidism nowadays. This systematic review followed the PRISMA methodology and analyzed recent literature from reliable sources such as PubMed, BVS and SciELO (2022-2024), which highlight the efficacy of cinacalcet in the management of secondary hyperparathyroidism, particularly in patients with CKD. The reviewed studies corroborate that cinacalcet not only regulates PTH levels but also improves clinical outcomes and reduces the morbidity and mortality associated with this condition. Since its introduction in 2004, cinacalcet has proven to be an effective nonsurgical alternative to parathyroidectomy, offering a solution for patients unsuitable for this type of intervention.
Downloads
References
Vallumsetla N, Mundi MS, Kennel KA. Secondary Hyperparathyroidism. Hyperparathyroidism: A Clinical Casebook [Internet]. 2023 [citado 05/07/2024];169–78. Disponible en:
https://www.ncbi.nlm.nih.gov/books/NBK557822/
Rathod VD, Paganelli S, Kočevar M, Krivec M, Piccolo O. Improved Process for the Synthesis of 3-(3-Trifluoromethylphenyl)propanal for More Sustainable Production of Cinacalcet HCl †. Molecules [Internet]. 2023 [citado 05/07/2024];28(16):6042. Disponible en: https://www.mdpi.com/1420-3049/28/16/6042/htm
Villarroel-Heise P, Ardiles-Arnaiz L, Cifuentes-Köster M, Peña-D’Ardaillon F, Lorca-Herrera E, Reyes-Jedlicki M, et al. Uso de cinacalcet en hiperparatiroidismo secundario: evaluación del estado nutricional, lipídico e inflamatorio en enfermedad renal crónica. Nutr Hosp [Internet]. 2023 [citado 05/07/2024];40(6):1236–45. Disponible en:
Alvarado L, Sharma N, Lerma R, Dwivedi A, Ahmad A, Hechanova A, et al. Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients. World J Surg [Internet]. 2022 [citado 05/07/2024];46(4):813–9. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1007/s00268-022-06439-7
Junaid SZS, Patel P, Patel JB. Cinacalcet. xPharm: The Comprehensive Pharmacology Reference [Internet]. 2024 [citado 05/07/2024];1–4. Disponible en:
https://www.ncbi.nlm.nih.gov/books/NBK557658/
Nakamura H, Tokumoto M, Anayama M, Kurihara S, Makino Y, Tamura K, et al. A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride. CEN Case Rep [Internet]. 2022 [citado 05/07/2024];11(2):254. Disponible en: https://pmc/articles/PMC9061916/
Wang AX, Liu S, Montez-Rath ME, Chertow GM, Lenihan CR. Parathyroidectomy and Cinacalcet Use in Medicare-Insured Kidney Transplant Recipients. American Journal of Kidney Diseases [Internet]. 2023 Mar 1 [cited 2024 Jul 5];81(3):270-280.e1. Disponible en: http://www.ajkd.org/article/S0272638622009155/fulltext
Bernardor J, De Mul A, Bacchetta J, Schmitt CP. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients. Curr Osteoporos Rep [Internet]. 2023 [citado 05/07/2024];21(2):193–204. Disponible en: https://link.springer.com/article/10.1007/s11914-023-00782-x
Li X, Ding W, Zhang H. Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review. Front Endocrinol (Lausanne). 2023 [citado 19/07/2024];19;14:1146955. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC10395090/pdf/fendo-14-1146955.pdf
Komaba H, Hamano T, Fujii N, Moriwaki K, Wada A, Masakane I, et al. Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis. J Clin Endocrinol Metab [Internet]. 2022 [citado 05/07/20245];107(7):2016–25. Disponible en: https://dx.doi.org/10.1210/clinem/dgac142
Al-Homrany M, Saeed M, Ali F, Al-Ghamdi S, Mousa D, Alharbi A. The Effectiveness of Alternate-day Cinacalcet Therapy for Secondary Hyperparathyroidism in Noncompliant Hemodialysis Patients. Saudi Journal of Kidney Diseases and Transplantation [Internet]. 2022 Jul 1 [cited 2024 Jul 5];33(4):503–8. Disponible en:
Liu J, Guo H, Lin TC, Wetmore JB, Bradbury BD, Gilbertson DT, et al. Cinacalcet and gastrointestinal bleeding risk in patients receiving hemodialysis. Pharmacoepidemiol Drug Saf [Internet]. 2022 [citado 05/07/2024];31(2):141–8. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/pds.5337
Wakamatsu T, Yamamoto S, Matsuo K, Taniguchi M, Hamano T, Fukagawa M, et al. Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials. J Bone Miner Metab [Internet]. 2024 [citado 05/07/2024];42(3):316–25. Disponible en: https://link.springer.com/article/10.1007/s00774-024-01500-y
Zamoner SMS, Takase HM, Riyuzo MC, Caramori JCT, de Andrade LGM. Safety of cinacalcet in children and adolescents with chronic kidney disease-mineral bone disorder: systematic review and proportional meta-analysis of case series. Int Urol Nephrol [Internet]. 2024 [citado 05/07/2024];56(5):1669–76. Disponible en: https://link.springer.com/article/10.1007/s11255-023-03844-2
Ponce D, de Almeida Cardoso MM, Rúgolo JRM, Molina SA, de Andrade LGM, da Silva Pereira Curado D. Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease. Brazilian Journal of Nephrology [Internet]. 2023 [citado 05/07/2024];45(3):369–76. Disponible en:
https://www.scielo.br/j/jbn/a/ny3NBkQRMqnLKKyzZC7ssWK/?lang=en
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic Reviews 2021;10:89. doi: https://doi.org/10.1186/s13643-021-01626-4
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Karen Gabriela Sulca Espín, John Sebastián Carvajal Gavilanes, Miguel Alejandro Alvarado Salan, Alex Ramón Valencia Herrera
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
ACCESS AND DISTRIBUTION POLICY
All published articles are open access contributions, which are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is properly cited.
